FAHIMA HASAN: Open Payments
NPI 1043933740 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,456 in 82 payments from 18 companies in 2025. Trend: 2023 $630 · 2024 $1,544 · 2025 $1,456
Food & beverage: $1,456
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $318 |
| Otsuka America Pharmaceutical, Inc. | 15 | $285 |
| Biogen, Inc. | 4 | $94 |
| Janssen Pharmaceuticals, Inc | 3 | $89 |
| Supernus Pharmaceuticals, Inc. | 2 | $83 |
| E.R. Squibb & Sons, L.L.C. | 5 | $74 |
| Axsome Therapeutics, Inc. | 4 | $73 |
| Lundbeck LLC | 3 | $60 |
| Gilead Sciences, Inc. | 3 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
Products named: VRAYLAR, REXULTI, ABILIFY MAINTENA, ZURZUVAE, Qelbree, COBENFY, Auvelity, SPRAVATO.
Industry payments across NE — which companies pay providers there.
